BioAlliance Pharma SA in Paris, France say it has been granted a European patent protecting its product acyclovir Lauriad. This patent, says the company, specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing, and its clinical application.
According to BioAlliance Pharma, acyclovir Lauriad provides treatment of recurrent herpes labialis with one tablet application as soon as the first signs of infection appear. The company says its patent portfolio now consists of 34 families of published patents, including 358 patent applications.
RSS - Posts